Remote Ischemic Conditioning for Limited Mobility
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how remote ischemic conditioning (RIC) can improve muscle strength, exercise tolerance, and quality of life for individuals over 65 with mobility challenges. RIC involves temporarily restricting blood flow to a limb, potentially enhancing the benefits of regular exercise. The study includes two groups: one receiving a high dose of RIC and the other a low dose, both combined with low-intensity resistance exercise. Ideal participants are those referred to an exercise program due to balance problems or muscle weakness. As an unphased trial, this study offers participants the chance to contribute to innovative research that could enhance exercise benefits for seniors.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that this technique is safe for individuals with limited mobility?
Studies have shown that remote ischemic conditioning (RIC) is generally safe for people. Research indicates that RIC is well-tolerated by various groups, including those with neurological disorders and children with cerebral palsy, meaning most did not experience serious side effects. Additionally, a study found that combining RIC with exercise was safe for individuals recovering from a stroke.
Overall, these findings suggest that RIC is a promising and safe addition to exercise programs, particularly for older adults with mobility issues.12345Why are researchers excited about this trial?
Researchers are excited about Remote Ischemic Conditioning (RIC) for people with limited mobility because it offers a novel approach compared to traditional physical therapy and medications. RIC involves temporarily restricting blood flow to a limb using a cuff, which can trigger beneficial responses throughout the body and potentially enhance muscle strength and endurance without intense physical exertion. This technique is especially promising for individuals who can't engage in regular exercise due to mobility issues, providing a safer and more accessible option. By using both high-dose and low-dose interventions, researchers hope to determine the most effective way to harness these benefits.
What evidence suggests that remote ischemic conditioning is effective for improving mobility?
Research has shown that remote ischemic conditioning (RIC) can improve health outcomes for various conditions. Studies have found that RIC reduces the risk of tissue damage after a stroke and aids in recovery. By temporarily stopping blood flow to an arm or leg, RIC appears to help the body better cope with stress. This trial will compare two doses of RIC: a high-dose intervention and a low-dose intervention. This technique has also shown promise in boosting muscle strength and resilience in other situations. Although specific data on improving mobility in older adults is limited, the mechanism of RIC suggests it could be beneficial.678910
Who Is on the Research Team?
W Todd Cade, PhD
Principal Investigator
Duke University
Are You a Good Fit for This Trial?
This trial is for people over 65 who have trouble moving around, possibly due to aging, weakness, or frailty. Participants should be able to perform some low-intensity exercises and must not have conditions that would make the trial unsafe or unsuitable for them.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo low-intensity resistance exercise training combined with either high-dose or low-dose remote ischemic conditioning (RIC)
Follow-up
Participants are monitored for changes in muscle strength, physical function, and resilience
What Are the Treatments Tested in This Trial?
Interventions
- Remote Ischemic Conditioning (RIC)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Duke University
Lead Sponsor
National Institutes of Health (NIH)
Collaborator